TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01976637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no compression
Description: no compression stockings worn during the study

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: compression
Description: compression stockings class II (23-32 mm Hg) worn during the day for up to 3 weeks
Study: NCT01984398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Androxal Formulation B
Description: Single dose of 25 mg Androxal formulation B
Study: NCT04296799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMP-100
Description: SAD/MAD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMP-100
Description: SAD/MAD
Study: NCT02048761

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: After debridement, a single dose of the placebo gel was applied into the periodontal pockets with a syringe and a blunt canula

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 % Metformin gel
Description: After debridement, 1% Metformin gel gel was applied into the periodontal pockets with a syringe and a blunt canula.
Study: NCT00585897

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: discontinuation of sugar sweetened beverages
Description: Individual sessions which utilize motivational interviewing to assist participants to eliminate sugar sweetened beverages from their diet.
Study: NCT04296799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT00767000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0941
Description: MK-0941 tablets three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0941
Description: MK-0941 tablets three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0941
Description: MK-0941 tablets three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0941
Description: MK-0941 tablets three times daily
Study: NCT03768388

Intervention type: DRUG
Group type: OTHER
Intervention: levoketoconazole
Description: food effect

Intervention type: DRUG
Group type: OTHER
Intervention: levoketoconazole
Description: food effect
Study: NCT02368769

Intervention type: DEVICE
Intervention: During Tele-expertise
Study: NCT00767000

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Matching placebo to MK-0941 three times daily
Study: NCT04503031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TaperGuard endotracheal tube
Description: TaperGuard endotracheal tube is intubated

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cylindrical endotracheal tube
Description: endotracheal tube is intubated
Study: NCT00767000

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lantus
Description: Lantus injection once daily

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lantus
Description: Lantus injection once daily

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lantus
Description: Lantus injection once daily

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lantus
Description: Lantus injection once daily

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Lantus
Description: Lantus injection once daily
Study: NCT03469362

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Urinary Diversion
Description: Extra-corporeal urinary diversion, provided as part of standard of care, will have the ureters sutured into the ileal conduit by hand.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracorporal Urinary Diversion
Description: Intracorporal Urinary Diversion, provided as part of standard of care, will have the ureters sutured into the ileal conduit using the Da Vinci robot.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Da Vinci Robot
Description: Da Vinci Robotic Surgical System
Study: NCT05179486

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of tissue, and blood

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT02462239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-body FDG PET-CT
Study: NCT00767000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin ≥1500 mg/day at a stable dose for at least 6 weeks before Screening and for the duration of the study. The number of randomized participants who receive metformin will be capped at 70% of enrollment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin ≥1500 mg/day at a stable dose for at least 6 weeks before Screening and for the duration of the study. The number of randomized participants who receive metformin will be capped at 70% of enrollment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin ≥1500 mg/day at a stable dose for at least 6 weeks before Screening and for the duration of the study. The number of randomized participants who receive metformin will be capped at 70% of enrollment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin ≥1500 mg/day at a stable dose for at least 6 weeks before Screening and for the duration of the study. The number of randomized participants who receive metformin will be capped at 70% of enrollment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin ≥1500 mg/day at a stable dose for at least 6 weeks before Screening and for the duration of the study. The number of randomized participants who receive metformin will be capped at 70% of enrollment.
Study: NCT03454672

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tixel
Description: Tixel treatment. Between 3-5 treatment sessions according to investigator's review of subject response.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Tixel treatment. Between 3-5 treatment sessions according to investigator's review of subject response.
Study: NCT03860987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin
Description: Goserelin will be administered SC at 10.8 mg every 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide will be given orally at 160mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone will be taken orally at 1000 mg once daily
Study: NCT02999308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observe the patient's condition and then change the regimen
Description: The patients will be assessed every 3 months and the treatment regimen will be modified by the result of assessment.
Study: NCT03120104

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor muscle exercise before stoma closure
Description: pelvic floor muscle training for one month (2\~3 times a week, for 4 weeks) just one month before the stoma closure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor muscle exercise after stoma closure
Description: pelvic floor muscle training for one month (2\~3 times a week, for 4 weeks) just two weeks after the stoma closure
Study: NCT03860987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: 18F-labeled agent that is a high affinity small molecule inhibitor of PSMA to detect prostate cancer via PET imaging
Study: NCT03946332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercises
Description: patients will benefit regularly from a physical exercises program during their hospitalization. When going back home, they will be given a practical help kit with specific equipment (dumbbell, elastic), an actimeter with heart rate monitoring (in order to have an objective collection of the physical practice in addition to a self-evaluation) and a physical exercises program on paper and video supports, that patients would have learnt during their hospitalization.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Optional physical exercises
Description: patients will be proposed for the physical exercises and will practice them if they want.
Study: NCT00975975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Basiliximab given 1 time on Day +7 or Day +9.
Study: NCT01229345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Breakfast & exercise
Description: 1859 kJ breakfast vs fast, exercise at 60% maximum aerobic capacity to expend 1859 kJ.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Breakfast & exercise
Description: 1859 kJ breakfast vs fast, exercise at 60% maximum aerobic capacity to expend 1859 kJ.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Breakfast & exercise
Description: 1859 kJ breakfast vs fast, exercise at 60% maximum aerobic capacity to expend 1859 kJ.
Study: NCT04409964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: dexmedetomidine iv bolus followed by the infusion of 0.1-1 ug/kg/hr during general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: lidocaine iv bolus followed by the infusion of 1.5 mg/kg/hr during general anesthesia
Study: NCT03860987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be taken orally at 5mg twice a day for each dose, or 10 mg once a day. Doses should be taken about 12 or 24 hours apart

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Radical Prostatectomy
Study: NCT05088525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI for standard of care meniscus root repair surgery - noting with an added stabilization suture if it is able to successfully slow down the progression of osteoarthritis versus a standard root repair surgery.
Study: NCT04409964

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil Hydrochloride
Description: remifentanil iv infusion of 0.5-5 ng/ml (effect site concentration using TCI) during general anesthesia
Study: NCT05088525

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: MRI for standard of care meniscus root repair surgery - noting with an added stabilization suture if it is able to successfully slow down the progression of osteoarthritis versus a standard root repair surgery.
Study: NCT01361698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery (IMR)
Description: In this Danish trial IMR will be implemented in group format with 10 patients assigned to each group and two IMR facilitators, and the IMR program will require nine months of weekly sessions to complete.
Study: NCT03890861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Promotion of physical activity to the current federal physical activity guidelines.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Successful Aging
Description: Seminars of health topics related to aging in African Americans with light stretching and low intensity activites
Study: NCT04595565

Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: 2000 mg/m² day 1-14 q21 day cycle for eight cycles

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: AUC 5 q3w or AUC 1.5 weekly for eight 3 weekly cycles

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: 25mg/m3 weekly or 75 mg/m3 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: 10 mg/kg body weight on days 1, 8 q3w
Study: NCT04060927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SGRT
Description: Surface Guided Radiation Therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SGRT
Description: Surface Guided Radiation Therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SGRT
Description: Surface Guided Radiation Therapy
Study: NCT02799433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual services + HAP
Description: The HAP process includes child care center providers completing a self-assessment(s), setting improvement goals, receiving technical assistance materials, attending topic-specific workshops, improving best practices, re-self-assessment and qualification for a HAP award.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual services
Description: Control condition
Study: NCT01984723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: EVP-6124
Study: NCT04180826

Intervention type: OTHER
Intervention: Observational
Description: Initially, the patient will be placed in a strict supine position (at 0°) in his hospital bed, according to the usual care.~In a second step, the patient will be verticalized (from 0° to 90°). Intracranial hemodynamics parameters in supine position and during verticalization will be continuously recorded by attaching the ATYS TCD-X® transcranial Doppler helmet attached with glasses.~After 15 minutes of recording, the patient will be placed back in supine position. The end of the patient's participation in the study will correspond to the removal of the ATYS TCD-X® helmet.

Intervention type: OTHER
Intervention: Observational
Description: Initially, the patient will be placed in a strict supine position (at 0°) in his hospital bed, according to the usual care.~In a second step, the patient will be verticalized (from 0° to 90°). Intracranial hemodynamics parameters in supine position and during verticalization will be continuously recorded by attaching the ATYS TCD-X® transcranial Doppler helmet attached with glasses.~After 15 minutes of recording, the patient will be placed back in supine position. The end of the patient's participation in the study will correspond to the removal of the ATYS TCD-X® helmet.
Study: NCT04603924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: Niclosamide is an antihelmintic with in-vitro antiviral activity

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
Study: NCT01577134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social-cognitive resource intervention
Description: Intervention group that receives a behavior change technique intervention to increase volitional strategies and physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social-cognitive resource intervention
Description: Active control group that receives a behavior change technique intervention to increase volitional strategies and volunteering.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: no intervention
Description: Passive control group that receives no intervention until the 8.5 months follow-up. Subsequently, they receive the information by mail the active groups received within the intervention.
Study: NCT01717417

Intervention type: DEVICE
Intervention: miniscrew

Intervention type: DEVICE
Intervention: TPA
Study: NCT02031276

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: risankizumab IV
Description: risankizumab administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab IV
Description: risankizumab administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab IV
Description: risankizumab administered by IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: risankizumab SC
Description: risankizumab administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab SC
Description: risankizumab administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab SC
Description: risankizumab administered by SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for risankizumab administered by IV infusion
Study: NCT04400552

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ONS Pre-op + ONS Post-op
Description: Participants will consume the oral nutrition supplementation (ONS) in addition to normal diet for 14 days pre-operatively and post-operatively up to participants being discharged from the hospital.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ONS Pre-op + ONS Post-op + ONS Post-op 3 months
Description: Participants will consume the oral nutrition supplementation (ONS) in addition to normal diet for 14 days pre-operatively, post-operatively up to participants being discharged from the hospital and an extended oral nutrition supplementation post-operatively up to 3 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Usual intake Pre-op + ONS Post-op
Description: Participants will follow a meal plan of 2000 kcal / day using conventional foods for 14 days pre-operatively and consume oral nutrition supplementation (ONS) in addition to normal diet post-operatively up to participants being discharged from the hospital
Study: NCT03607578

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Other: Control Group - Minimal Intervention
Description: Basic Campaign Folder

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Protection Routine 1
Description: New folder, sun advice of Danish Sun Safety Campaign, rationale, prioritization, overview of sun prevention. Activity planner with outdoor activities like bathing, sports and excursions before and after noon (UVI maximum) and indoor activities; shopping, lunch, relaxation and transportation in middle of day and possibility to plan vacation to minimize risk. Instructions for download of UV-App includes use of alert, and information about the features of the app; how to be informed of current UV risk before and during vacation. Link for download of the app is sent by text-message and e-mail. Skintype guide is included in the app and as an individual entity. It includes scoring questions about tan and burn reaction in the sun, a color scale, eye and hair color and freckles. Participants get a description of their skin type and examples of time their particular skin type will resist the sun before erythema occurs at particular UV-levels and functions as an eye-opener.
Study: NCT03514121

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FPA150
Description: A monoclonal antibody against B7-H4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: An anti-PD1 antibody
Study: NCT03634007

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LX1001
Description: LX1001 is a serotype rh.10 AAV gene transfer vector expressing the cDNA coding for human APOE2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LX1001
Description: LX1001 is a serotype rh.10 AAV gene transfer vector expressing the cDNA coding for human APOE2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LX1001
Description: LX1001 is a serotype rh.10 AAV gene transfer vector expressing the cDNA coding for human APOE2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LX1001
Description: LX1001 is a serotype rh.10 AAV gene transfer vector expressing the cDNA coding for human APOE2.
Study: NCT04464200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 19(T2)28z1xx CAR T cells
Description: 2-7 days following the completion of the conditioning chemotherapy, patients will receive the CAR- T cells by IV infusion over 1-3 days depending on the dose level and formulation of the final CAR- T cells.
Study: NCT03582059

Intervention type: PROCEDURE
Group type: OTHER
Intervention: High Frequency Spinal cord stimulation
Description: An electrode will be implanted into the patients back. A defined stimulation patter will be applied. The patient will be randomised to received 7-10 days of high frequency stimulation.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: High Frequency Spinal cord stimulation
Description: An electrode will be implanted into the patients back. A defined stimulation patter will be applied. The patient will be randomised to received 7-10 days of high frequency stimulation.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Burst Frequency Spinal cord stimulation
Description: An electrode will be implanted into the patients back. A defined stimulation patter will be applied. The patient will be randomised to received 7-10 days of burst frequency stimulation.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Burst Frequency Spinal cord stimulation
Description: An electrode will be implanted into the patients back. A defined stimulation patter will be applied. The patient will be randomised to received 7-10 days of burst frequency stimulation.
Study: NCT03649256

Intervention type: DIAGNOSTIC_TEST
Intervention: Thickness of lower uterine segment scar
Description: Ultrasound measurement of thickness of the uterine scar at 3 and 6 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Thickness of lower uterine segment scar
Description: Ultrasound measurement of thickness of the uterine scar at 3 and 6 months
Study: NCT03101956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Spine Manipulation
Description: • The subject will be placed in sidelying on a treatment table. Facing the subject, the therapist will position the subject's superior thigh in flexion and rotate the subject's upper trunk to the opposite side. The therapist will place his cephalad forearm along the subject's superior lateral trunk and the caudal forearm along the subject's iliac crest and lateral hip. Lastly, the therapist will roll the subject towards himself or herself.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Spine Manipulation Placebo
Description: The subject will be placed in sidelying on a treatment table. Facing the subject, the therapist will position both hips and knees in approximately 45° of flexion. The therapist will place his or her cephalad forearm along the subject's superior lateral trunk and the caudal forearm along the subject's iliac crest and lateral hip. Lastly, the therapist will roll the subject towards himself or herself.
Study: NCT02585739

Intervention type: GENETIC
Group type: OTHER
Intervention: blood sample

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: blood sample